AGENUS INC Noncontrolling Interest, Increase from Subsidiary Equity Issuance
AGENUS INC (AGEN) reported Noncontrolling Interest, Increase from Subsidiary Equity Issuance of $1.01 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Shareholders' Equity › Noncontrolling Interest Items
us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance · last filed 2026-03-16
- AGENUS INC noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2023-06-30 was $285.00K, a 3.06% decline year-over-year.
- AGENUS INC noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2023-03-31 was $726.00K.
- AGENUS INC noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2022-06-30 was $294.00K.
- AGENUS INC noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2021-12-31 was $0.00.
- AGENUS INC noncontrolling interest, increase from subsidiary equity issuance for fiscal 2023 was $1.01M, a 243.88% increase from fiscal 2022.
- AGENUS INC noncontrolling interest, increase from subsidiary equity issuance for fiscal 2022 was $294.00K, a 97.06% decline from fiscal 2021.
- AGENUS INC noncontrolling interest, increase from subsidiary equity issuance for fiscal 2021 was $10.00M, a 321.23% increase from fiscal 2020.
- AGENUS INC noncontrolling interest, increase from subsidiary equity issuance for fiscal 2020 was $2.37M.
| Period end | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 3 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 6 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 9 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.01M 10-K · filed 2026-03-16 | |||
| 2023-06-30 | $285.00K 10-Q · filed 2024-11-12 | $1.01M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $726.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $294.00K 10-K · filed 2025-03-17 | |||
| 2022-06-30 | $294.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $10.00M derived: sum of 2 quarters · filed 2024-03-14 | $10.00M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $10.00M 10-Q · filed 2022-11-08 | $10.00M 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | $2.37M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |